Overview
DUBLIN-(BUSINES WIRE)-The "Diabetic Fot Ulcer Treatment Market Size, Share & Trends Analysis Report by Treatment (Biologics, Wound Care Dresings), by Ulcer Type (Neuro-ischemic, Ischemic, Neuropathic), by End-use, and Segment Forecasts, 202-2030" report has ben aded to ResearchAndMarkets.com's ofering. The global diabetic fot ulcer treatment market size is expected to reach USD 7.7 bilion by 2030, registering a CAGR of 5.9% from 202 to 2030, acording to this report.
Key Information
Diabetes is one of the major causes of amputation, blindnes, stroke, end-stage renal failure, kidney failure, and heart atacks in this region. Acording to the International Diabetes Federation, ~6 milion people were sufering from diabetes in Europe in 2017. The number is expected to increase to ~81 milion by 2045.
The mortality rate asociated with DFU is ~5% in the first 12 months and increases up to 42% by the end of 5 years. Many adjuvant therapies such as nonsurgical debridement agents, dresings and topical agents, oxygen therapies, negative presure wound therapy, acelular bioproducts, human growth factors, energy-based therapies, and systemic therapies are said to efectively improve and cure DFU. Recent studies sugest that the inhibition of detrimental proteinase MP-9 enzyme alows the body to heal the wound at a quicker rate.
Sedentary lifestyle, por GDP expenditure on healthcare, unhealthy fod habits, and por reimbursement scenarios in the Asian region are the factors responsible for the high growth of diabetes in this region. Hence, numerous il efects of DFU are observed in the Asian region. The biologics segment held the largest revenue share in 2021 and is expected to grow at the highest rate during the forecast period.
Summary
Biologics include growth factors [such as Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF)], stem cels, and other anti-diabetic drugs. These agents help reduce hyperglycemia, increase oxygenation and circula